Aceto Corporation (ACET)’s Financial Results Comparing With Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

We will be contrasting the differences between Aceto Corporation (NASDAQ:ACET) and Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) as far as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations are concerned. The two businesses are rivals in the Drugs - Generic industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aceto Corporation N/A 0.00 N/A -9.77 0.00
Synergy Pharmaceuticals Inc. N/A 0.00 N/A -0.56 0.00

Table 1 highlights Aceto Corporation and Synergy Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Aceto Corporation (NASDAQ:ACET) and Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Aceto Corporation 0.00% 0% 0%
Synergy Pharmaceuticals Inc. 0.00% 0% 0%

Insider & Institutional Ownership

The shares of both Aceto Corporation and Synergy Pharmaceuticals Inc. are owned by institutional investors at 35.91% and 15.36% respectively. About 9.46% of Aceto Corporation’s share are held by insiders. Insiders Comparatively, held 0.29% of Synergy Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aceto Corporation 0% 0% 0% 0% 0% 0%
Synergy Pharmaceuticals Inc. 0% 0% 0% 0% 0% 0%

Summary

Synergy Pharmaceuticals Inc. beats on 1 of the 1 factors Aceto Corporation.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment is also involved in developing and marketing generic pharmaceutical products. It sells its generic prescription and over the counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass market merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals for use in the manufacture of plastics, surface coatings, cosmetics and personal care products, textiles, and fuels and lubricants, as well as for food, flavor, paper, and film industries; dye and pigment intermediates used in the color-producing industries; and organic intermediates used in the production of agrochemicals. Its raw materials are also used in electronic parts for photo tooling, circuit boards, and production of computer chips. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.